Martin E. Cooper. Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837. // Obesity Reviews. – 2026. – DOI: 10.1111/obr.70166. – URL: https://onlinelibrary.wiley.com/doi/10.1111/obr.70166?af=R
Martin E. Cooper (2026). Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837. Obesity Reviews. https://doi.org/10.1111/obr.70166
Martin E. Cooper. “Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837.” Obesity Reviews, 2026. doi:10.1111/obr.70166.
@article{Cooper2026,
title = {Is Hepatic Cannabinoid 1 Receptor a Key Driver of Obesity? Implications of the Weight‐Reducing Efficacy of the Hepatotropic Inverse Agonist TM38837},
author = {Cooper, Martin E.},
journal = {Obesity Reviews},
year = {2026},
doi = {10.1111/obr.70166},
url = {https://onlinelibrary.wiley.com/doi/10.1111/obr.70166?af=R}
}